Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05464732 · ClinicalTrials.gov registry record · NA
Vivity IOL: Emmetropia Compared to Monovision.
A NA study, sponsored by Carolina Eyecare Physicians.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT05464732: Completed NA study, sponsored by Carolina Eyecare Physicians.
NCT05464732 is a NA study that has completed, run by Carolina Eyecare Physicians. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05464732, a NA study, has completed, sponsored by Carolina Eyecare Physicians.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Different options are available including: mono-vision and presbyopia correcting intraocular lenses (IOL). Presbyopia correcting IOLs include accommodative, multifocal, trifocal and extended depth of focus (EDOF) IOLs. The Vivity Extended Vision IOL is not a multifocal IOL but due to its design, it provides better intermediate and near VA compared to a monofocal IOL.
Primary Outcome
The logMAR binocular uncorrected visual acuity at 40 cm will be measured.
Interventions
- DEVICE Vivity IOL emmetropia
- DEVICE Vivity IOL monovision
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2022-08-30 |
| Phase | NA |
What the finished NCT05464732 record still lists
NCT05464732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Vivity IOL emmetropia is the first listed.
NCT05464732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05464732 about?
NCT05464732 is a clinical study titled "Vivity IOL: Emmetropia Compared to Monovision.". Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Different options are available including: mono-vision and presbyopia correcting intraocular le...
What is the current status of trial NCT05464732?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2020-09-03. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT05464732?
The interventions under investigation include: Vivity IOL emmetropia (DEVICE), Vivity IOL monovision (DEVICE).
Who is sponsoring clinical trial NCT05464732?
This trial is sponsored by Carolina Eyecare Physicians, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05464732's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI